Renvela (Sevelamer Carbonate) Patent Expiration, LOE Window & CMS Spending

Renvela (Sevelamer Carbonate) by Sanofi: FDA Orange Book LOE 2030-12-06, 18 AB generics, $67.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSanofi
FDA Application & PathwayN022127 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-12-06
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors18
2024 CMS Total Public Spend$67.9M
2024 Medicare Part D Spend$38.0M
2024 Medicaid Spend$29.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.